Journal
NATURE MEDICINE
Volume 22, Issue 9, Pages 991-+Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nm.4148
Keywords
-
Funding
- National Sci-Tech Support Program [2014BAI07B01]
- National Basic Research Program of China 973 Program [2014CB541903, 2014CB541901, 2010CB529104]
- National Natural Science Foundation of China (NSFC) [81373117, 31570880, 31530020, 81429003, 81471601]
- Beijing Key Laboratory for Rheumatism and Immune Diagnosis [BZ0135]
- Peking-Tsinghua Center for Life Sciences
- Priority Research Program of the Shandong Academy of Sciences
- Shandong Province Taishan Scholar Program
- Australian National Health and Medical Research Council (NHMRC) [GNT1085509]
Ask authors/readers for more resources
Systemic lupus erythematosus (SLE) is a potentially life-threatening autoimmune disease characterized by altered balance of activity between effector and regulatory CD4(+) T cells. The homeostasis of CD4(+) T cell subsets is regulated by interleukin (IL)-2, and reduced production of IL-2 by T cells is observed in individuals with SLE. Here we report that treatment with low-dose recombinant human IL-2 selectively modulated the abundance of regulatory T (T-reg) cells, follicular helper T (T-FH) cells and IL-17-producing helper T (T(H)17) cells, but not T(H)1 or T(H)2 cells, accompanied by marked reductions of disease activity in patients with SLE.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
